Galapagos NV (GLPG) Receives Media Sentiment Rating of 0.14
News coverage about Galapagos NV (NASDAQ:GLPG) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galapagos NV earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.742996523103 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Galapagos NV (GLPG) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Galapagos NV (GLPG) Stock Rating Reaffirmed by Morgan Stanley (americanbankingnews.com)
- ETFs with exposure to Galapagos NV : October 5, 2017 (finance.yahoo.com)
- Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron (finance.yahoo.com)
GLPG has been the subject of several recent research reports. BTIG Research reissued a “buy” rating and set a $98.00 target price on shares of Galapagos NV in a research note on Tuesday, June 20th. Cowen and Company reissued a “buy” rating on shares of Galapagos NV in a research note on Wednesday, June 21st. Nomura cut their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a research note on Thursday, June 22nd. Instinet reissued a “buy” rating and set a $108.00 target price (down from $121.00) on shares of Galapagos NV in a research note on Thursday, June 22nd. Finally, Janney Montgomery Scott raised shares of Galapagos NV from a “sell” rating to a “neutral” rating in a research note on Friday, July 7th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $108.14.
Shares of Galapagos NV (NASDAQ:GLPG) opened at 101.63 on Monday. Galapagos NV has a 1-year low of $57.16 and a 1-year high of $103.97.
TRADEMARK VIOLATION NOTICE: “Galapagos NV (GLPG) Receives Media Sentiment Rating of 0.14” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/galapagos-nv-glpg-receives-media-sentiment-rating-of-0-14/1618678.html.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.